8.2 Federal Anti-Tampering Act & Over-the-Counter Regulations

8.2 Federal Anti-Tampering Act & Over-the-Counter Regulations

[!NOTE] Core Statutory & Regulatory Authorities: Over-the-counter (OTC) drug security and chemical precursor control are governed by the Federal Anti-Tampering Act (18 U.S.C. § 1365; 21 CFR § 211.132), the Combat Methamphetamine Epidemic Act of 2005 (CMEA, Title VII of Public Law 109-177; 21 U.S.C. § 830; 28 CFR Part 1314), and the New Jersey Controlled Dangerous Substances Act (N.J.S.A. 24:21-1 et seq.; N.J.A.C. 13:45H).

Over-the-counter medications represent a vital segment of consumer healthcare, allowing individuals to self-treat minor ailments without professional medical intervention. However, because OTC products reside on open commercial shelving accessible to the general public, they present distinct safety, malicious tampering, and chemical diversion risks. Candidates preparing for the New Jersey MPJE must master the physical packaging requirements established under federal anti-tampering statutes, retail sales volume limits and logbook requirements for methamphetamine precursors under the CMEA, and the critical jurisdictional boundary where New Jersey law strictly overrides federal allowances regarding Schedule V codeine cough preparations.

---

The Federal Anti-Tampering Act of 1983 (18 U.S.C. § 1365)

Historical Catalyst: The 1982 Chicago Tylenol Poisonings

In autumn 1982, seven individuals in the Chicago metropolitan area died after ingesting Extra-Strength Tylenol capsules that had been laced with lethal doses of potassium cyanide. An unknown perpetrator had removed bottles from retail store shelves, opened the two-piece gelatin capsules, introduced cyanide powder, and returned the tainted bottles to store shelves. The tragedy shattered consumer confidence and exposed vulnerabilities in retail drug distribution.

In response, Congress enacted the Federal Anti-Tampering Act of 1983 (18 U.S.C. § 1365), making it a federal felony offense to tamper with consumer products. The statute penalizes five distinct criminal offenses:

1. Tampering with any consumer product that affects interstate or foreign commerce with reckless disregard for the risk of death or bodily injury.
2. Tainting a consumer product with intent to cause serious injury.
3. Communicating false information that a consumer product has been tainted.
4. Threatening to tamper with a consumer product.
5. Conspiring to tamper or attempt to tamper with a consumer product.

Penalties range from substantial fines and 10 to 20 years of federal imprisonment, extending to life imprisonment or the death penalty if death results from the tampering.

---

FDA Tamper-Evident Packaging Regulations (21 CFR § 211.132)

To operationalize the statute, the FDA promulgated mandatory tamper-evident packaging regulations codified at 21 CFR § 211.132:

1. Mandatory Product Scope

Tamper-evident packaging is mandatory for all retail OTC human drug products, including:

• Oral solid dosage forms (tablets, capsules, caplets);
• Oral liquid dosage forms (syrups, elixirs, suspensions);
• Liquid ophthalmic, otic, and nasal solutions;
• Rectal and vaginal drug products;
• Contact lens solutions and tablets.
• Exemptions: OTC products not susceptible to malicious tampering, such as dermatological topicals, dentifrices (toothpaste), insulin, and throat lozenges.

2. Regulatory Definition & Design Requirements

Under 21 CFR § 211.132(b), a tamper-evident package is defined as:

"A package having one or more indicators or barriers to entry which, if breached or missing, can reasonably be expected to provide visible evidence to consumers that tampering has occurred."

To prevent counterfeit seals, the barrier must be distinctive by design:

• It must use an identifying characteristic (such as a company logo, pattern, trademark, or unique text) that cannot be readily duplicated using commercially available packaging materials or printing equipment.
• Accepted Technologies: Heat-induction foil inner mouth seals, custom-printed plastic bottle-neck shrink bands, blister packaging, breakable threaded cap rings, glued carton flaps with tear strips, sealed aerosol containers, and film wrappers with printed tear-tape.

3. Special Standard for Two-Piece Hard Gelatin Capsules

Because two-piece hard gelatin capsules can be easily separated, contaminated, and rejoined without visible damage, the FDA enforces heightened standards:

• Two-piece hard gelatin capsules must be sealed using at least two (2) separate tamper-evident features (e.g., a shrink band around the neck plus a foil seal over the bottle opening), OR
• The capsule shell itself must be treated with an acceptable capsule-sealing technology (such as gelatin banding or heat-welding that fuses the two halves of the capsule into a single unopenable unit), which counts as one of the required features.

4. Mandatory Consumer Alert Labeling

Under 21 CFR § 211.132(c), the package must display a prominent, conspicuous statement alerting the consumer to the specific tamper-evident feature:

• The statement must be placed so that it remains intact and visible even if the tamper-evident barrier is breached or removed.
• Representative Labeling: "For your protection, do not use if printed safety seal under bottle cap is broken, torn, or missing."

---

Combat Methamphetamine Epidemic Act of 2005 (CMEA)

The Combat Methamphetamine Epidemic Act of 2005 (CMEA; 21 U.S.C. § 830; 28 CFR Part 1314) was enacted to curb the illicit domestic production of methamphetamine. Methamphetamine is synthesized through the chemical reduction of three regulated precursor chemicals known as Scheduled Listed Chemical Products (SLCPs):

1. Pseudoephedrine (PSE)
2. Ephedrine (EPH)
3. Phenylpropanolamine (PPA) (Note: PPA is largely withdrawn from human OTC medications due to hemorrhagic stroke risks, but remains regulated as an SLCP)

+---------------------------------------------------------------------------------------------------+
|                         CMEA RETAIL SALES RESTRICTIONS & TRANSACTION CAPS                         |
+---------------------------------------------------------------------------------------------------+
| Regulatory Threshold                  | Statutory Limit (Expressed in Base Chemical Equivalent)   |
+---------------------------------------+-----------------------------------------------------------+
| **Daily Retail Sales Limit**          | Maximum **3.6 grams** per purchaser per calendar day      |
|                                       | (Regardless of the number of retail transactions)         |
+---------------------------------------+-----------------------------------------------------------+
| **30-Day Retail Sales Limit**         | Maximum **9.0 grams** per purchaser per 30-day period     |
|                                       | (Rolling 30-day window across retail brick-and-mortar)    |
+---------------------------------------+-----------------------------------------------------------+
| **30-Day Mail-Order / Mobile Limit**  | Maximum **7.5 grams** per purchaser per 30-day period     |
|                                       | (Applies to mail-order, internet, and mobile kiosks)      |
+---------------------------------------+-----------------------------------------------------------+
| **Non-Logbook "60 mg Exemption"**     | Package containing **<= 60 mg** of pseudoephedrine total  |
|                                       | (Exempt from logbook and ID; STILL subject to caps & BTC) |
+---------------------------------------+-----------------------------------------------------------+

Salt-to-Base Calculations: The High-Yield Math of CMEA

The statutory caps under 21 U.S.C. § 830 are calculated strictly according to the base chemical weight, not the total salt weight. In commercial pharmacy products, pseudoephedrine is formulated as either Pseudoephedrine Hydrochloride (HCl) or Pseudoephedrine Sulfate:

$\text{Pseudoephedrine HCl (MW 201.7 g/mol)} \longrightarrow \text{Base constitutes } \approx \mathbf{81.9\%} \text{ of salt weight}$ $\text{Pseudoephedrine Sulfate (MW 428.5 g/mol)} \longrightarrow \text{Base constitutes } \approx \mathbf{77.0\%} \text{ of salt weight}$

[!TIP] Exam Calculation Shortcut: On the MPJE, a 30 mg Pseudoephedrine HCl tablet equals 24.6 mg of base. A standard box of 24 tablets (30 mg each) contains $24 \times 24.6\text{ mg} = 590.4\text{ mg}$ (approximately 0.59 g) of base. A purchaser can buy up to 6 boxes ($6 \times 0.59\text{ g} = 3.54\text{ g} \le 3.6\text{ g}$) in a single day.

---

Packaging, Storage & Physical Security Rules

Under 21 U.S.C. § 830(d) and 28 CFR Part 1314, retail establishments stocking SLCPs must comply with strict physical security standards:

• Blister Packaging Mandate: All non-liquid SLCP dosage forms (tablets, capsules) must be packaged in blister packs, with each blister containing not more than two (2) dosage units. If blister packaging is technically unfeasible, unit-dose packets must be utilized.
• Storage Placement: Regulated products must be stored behind the dispensing pharmacy counter (Behind-The-Counter / BTC) OR housed within a locked display case or cabinet located in an area accessible only to retail pharmacy personnel.

---

Mandatory Logbook & Verification Protocols (NPLEx)

Every regulated retail seller must capture every SLCP transaction in a written or electronic logbook. In New Jersey, retail pharmacies integrate directly with the National Precursor Log Exchange (NPLEx), a real-time multi-state database:

1. Purchaser Obligations

• Must present an unexpired, government-issued photo identification card (e.g., New Jersey driver’s license, non-driver state ID, U.S. passport, military ID).
• Must sign the logbook (via digital electronic signature capture pad or bound physical signature log).
• Must enter or confirm their printed legal name, residential street address, and the date and time of the purchase.

2. Pharmacy Staff Verification Obligations

• The retail employee must inspect the photo ID and verify that the photograph matches the customer and that the name matches the logbook entry.
• The employee must enter the product name, dosage, and exact quantity (grams of base) sold.
• The system performs a real-time query against NPLEx to calculate the purchaser's rolling 30-day purchase total across all participating retailers. If the transaction exceeds 3.6 g daily or 9.0 g within 30 days, the system generates a "Stop Sale" alert, and the transaction must be declined.

3. The "60 mg Exemption"

• Federal law creates a narrow exemption for minor single-dose purchases: transactions involving not more than 60 mg of pseudoephedrine total (such as a single travel packet containing two 30 mg tablets or one 60 mg tablet) do NOT require an electronic logbook entry or photo ID verification.
• Crucial Limitation: The product MUST STILL BE STORED BEHIND THE COUNTER, and the quantity sold still counts toward the purchaser's daily 3.6 g and monthly 9.0 g caps.

4. Record Retention & Inspection

• All logbook records (written or electronic) must be retained for at least two (2) years from the date of the transaction.
• Records must be maintained securely to protect purchaser privacy and must be made readily available for inspection by authorized DEA agents and law enforcement officials.

5. Annual DEA Employee Training Self-Certification

• Any retail pharmacy, grocery store, or distributor that sells SLCPs at retail must complete an annual self-certification with the DEA via the DEA Diversion Control Division portal.
• The retailer must certify that every employee who engages in SLCP sales has successfully undergone training on CMEA rules, product placement, identification checks, and logbook compliance.
• Records of employee training certifications must be maintained in the pharmacy and updated annually.

---

CRITICAL NEW JERSEY DISTINCTION: Schedule V Codeine Cough Syrups

One of the most heavily tested distinction areas on the New Jersey MPJE involves the retail sale of Schedule V controlled substances containing codeine (e.g., Cheratussin AC, Robitussin AC, guaifenesin with codeine syrup 10 mg/5 mL):

1. The Federal Baseline (21 CFR § 1306.26)

Under federal DEA regulations, certain Schedule V controlled substances that are not prescription legend drugs under the FD&C Act may be sold at retail without a prescription ("exempt narcotic sales") provided that:

• The sale is made only by a licensed pharmacist (cash transaction may be completed by an assistant);
• The purchaser is at least 18 years of age and presents valid photo ID;
• Not more than 240 mL (8 oz) or 48 dosage units of any preparation containing opium, or not more than 120 mL (4 oz) or 24 dosage units of any other controlled substance (including codeine) is sold to the same purchaser in any 48-hour period;
• A bound, consecutive Schedule V record book is maintained recording purchaser name, address, drug name, quantity, date, and dispensing pharmacist initials.

2. The Strict New Jersey Prohibition (N.J.S.A. 24:21-1; N.J.A.C. 13:45H)

New Jersey law is significantly more restrictive than the federal baseline:

[!WARNING] NEW JERSEY MPJE ABSOLUTE RULE: Under the New Jersey Controlled Dangerous Substances Act (N.J.S.A. 24:21-1 et seq.) and the implementing regulations of the Board of Pharmacy and Division of Consumer Affairs (N.J.A.C. 13:45H), ALL PREPARATIONS CONTAINING CODEINE—REGARDLESS OF SCHEDULE OR LOW CONCENTRATION—REQUIRE A VALID PRESCRIPTION FROM A LICENSED PRESCRIBER.

• Exempt OTC Sales of Codeine are ILLEGAL in New Jersey.
• A retail pharmacist in New Jersey CANNOT sell Cheratussin AC, Robitussin AC, or any codeine-containing cough preparation over-the-counter without a prescription.
• Any pharmacist who dispenses a codeine syrup without a valid prescription violates New Jersey controlled substance law and faces criminal charges and Board license revocation.

+---------------------------------------------------------------------------------------------------+
|                 SCHEDULE V CODEINE COUGH SYRUP: FEDERAL VS. NEW JERSEY JURISDICTION               |
+---------------------------------------------------------------------------------------------------+
| Legal Parameter                       | Federal Law (21 CFR § 1306.26)    | New Jersey Law (N.J.S.A. 24:21) |
+---------------------------------------+-----------------------------------+---------------------------------+
| **Prescription Required?**            | NO (Permits OTC exempt sale)      | **YES (MANDATORY PRESCRIPTION)**|
| **Quantity Cap**                      | Max 120 mL (4 oz) per 48 hours    | N/A (Prescription required)     |
| **Bound Logbook Record**              | Required for OTC sales            | N/A (Prescription required)     |
| **Governing Standard**                | Regulatory floor (least strict)   | **Controls in NJ (STRICTEST)**  |
+---------------------------------------+-----------------------------------+---------------------------------+

---

Summary of Key Exam Traps